NCT07132918 2026-03-11
HEARTS Trial for Thoracic Cancers
University of Wisconsin, Madison
Phase 2 Recruiting
Clinical Trials
13 trialsNCT03295227 2026-01-30
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06838910 2025-12-01
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT03463460 2025-08-24
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06186726 2025-06-13
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Shanghai Proton and Heavy Ion Center
Phase 2 Recruiting
NCT05667948 2025-05-22
Molecular Analysis and Treatment Options of Thymic Malignancies
Shanghai Chest Hospital
Recruiting
NCT06692062 2024-11-18
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Xiangya Hospital of Central South University
Phase NA Recruiting
NCT05214612 2024-07-31
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Assiut University
Recruiting
NCT06402708 2024-05-10
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
Fudan University
Phase 3 Recruiting
NCT06301945 2024-03-27
INTHYM
Erasmus Medical Center
Recruiting
NCT02633553 2023-12-08
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Fudan University
Phase NA Recruiting
NCT02633514 2023-12-05
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Fudan University
Phase 3 Recruiting